Patent Application: Reversing Dexmedetomidine Sedation

This document is a published patent application from the USPTO, specifically application US20260083689A1, filed on October 7, 2025. It describes novel methods and compositions, including those for intravenous administration, that utilize dextroamphetamine and/or lisdexamfetamine to reverse sedation caused by dexmedetomidine. The inventors listed are Ken Solt, Oluwaseun Johnson-Akeju, and Emery N. Brown.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in pharmaceutical treatments for anesthesia reversal. Companies involved in anesthesia, sedation, or critical care may wish to monitor the progress of this patent application and related research for potential impacts on drug development and clinical practice.